Search

Your search keyword '"El-Hariry, Iman A."' showing total 188 results
Start Over Author "El-Hariry, Iman A."
188 results on '"El-Hariry, Iman A."'

1. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial

Author

Hammel, Pascal, Fabienne, Portales, Mineur, Laurent, Metges, Jean-Philippe, Andre, Thierry, De La Fouchardiere, Christelle, Louvet, Christophe, El Hajbi, Farid, Faroux, Roger, Guimbaud, Rosine, Tougeron, David, Bouche, Olivier, Lecomte, Thierry, Rebischung, Christine, Tournigand, Christophe, Cros, Jerome, Kay, Richard, Hamm, Adam, Gupta, Anu, Bachet, Jean-Baptiste, and El Hariry, Iman

Published
2020
Full Text
View/download PDF

2. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Author

Goldman, Jonathan W, Raju, Robert N, Gordon, Gregory A, El-Hariry, Iman, Teofilivici, Florentina, Vukovic, Vojo M, Bradley, Robert, Karol, Michael D, Chen, Yu, Guo, Wei, Inoue, Takayo, and Rosen, Lee S

Abstract

Abstract Background This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies. Methods Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 hour IV infusion, once weekly for 3 weeks, followed by a 1-week rest until disease progression or unacceptable toxicity. Endpoints included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clinical activity. Results Fifty-three patients were treated at doses escalating from 7 to 259 mg/m2. The most common adverse events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting. Dose-limiting toxicities (DLT) observed were: one Grade 3 amylase elevation (150 mg/m2), one Grade 3 diarrhea and one Grade 3 and one Grade 4 asthenia (259 mg/m2). The MTD was 216 mg/m2 and the recommended phase 2 dose was established at 200 mg/m2 given IV at Days 1, 8, and 15 every 4 weeks. There was a linear relationship between dose and exposure. Plasma HSP70 protein levels remained elevated for over a week post treatment. Disease control rate (objective response and stable disease at ≥ 16 weeks) was 24.4%. Conclusions Ganetespib is well tolerated as a weekly infusion for 3 of every 4 weeks cycle. The recommended phase II dose is 200 mg/m2, and is associated with an acceptable tolerability profile. Trial registration NCT00687934

Published
2013

3. A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.

Author

Yin, Chao, primary, Marshall, John, additional, Macke, Laura Ann, additional, He, Aiwu Ruth, additional, Bouker, Kerrie, additional, Weinberg, Benjamin Adam, additional, Mukherji, Reetu, additional, Weiner, Louis M., additional, Wang, Hongkun, additional, Geng, Xue, additional, Hoke, Frank, additional, Youssoufian, Hagop, additional, El-Hariry, Iman, additional, and Noel, Marcus Smith, additional

Published
2023
Full Text
View/download PDF

5. Data from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 1 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 4 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Methods and Figure Legends from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 3 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 1 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 4 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Methods from A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

Author

Socinski, Mark A., primary, Goldman, Jonathan, primary, El-Hariry, Iman, primary, Koczywas, Marianna, primary, Vukovic, Vojo, primary, Horn, Leora, primary, Paschold, Eugene, primary, Salgia, Ravi, primary, West, Howard, primary, Sequist, Lecia V., primary, Bonomi, Philip, primary, Brahmer, Julie, primary, Chen, Lin-Chi, primary, Sandler, Alan, primary, Belani, Chandra P., primary, Webb, Timothy, primary, Harper, Harry, primary, Huberman, Mark, primary, Ramalingam, Suresh, primary, Wong, Kwok-Kin, primary, Teofilovici, Florentina, primary, Guo, Wei, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Methods, Figure Legend from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 3 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 2 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

18. A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

Author

Jhaveri, Komal, Chandarlapaty, Sarat, Lake, Diana, Gilewski, Teresa, Robson, Mark, Goldfarb, Shari, Drullinsky, Pamela, Sugarman, Steven, Wasserheit-Leiblich, Carolyn, Fasano, Julie, Moynahan, Mary Ellen, D'Andrea, Gabriella, Lim, Kristina, Reddington, Laura, Haque, Sofia, Patil, Sujata, Bauman, Lynne, Vukovic, Vojo, El-Hariry, Iman, Hudis, Clifford, and Modi, Shanu

Published
2014
Full Text
View/download PDF

20. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

Author

Harrington, Kevin, Berrier, Alain, Robinson, Martin, Remenar, Eva, Housset, Martin, de Mendoza, Fernando Hurtado, Fayette, Jérôme, Mehanna, Hisham, El-Hariry, Iman, Compton, Natalie, Franklin, Natalie, Biswas-Baldwin, Nigel, Lau, Mike, Legenne, Philippe, and Kumar, Rejnish

Published
2013
Full Text
View/download PDF

21. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia

Author

Lynggaard, Line Stensig, Vaitkeviciene, Goda, Langenskiöld, Cecilia, Lehmann, Anne Kristine, Lähteenmäki, Päivi M, Lepik, Kristi, El Hariry, Iman, Schmiegelow, Kjeld, Albertsen, Birgitte Klug, Lynggaard, Line Stensig, Vaitkeviciene, Goda, Langenskiöld, Cecilia, Lehmann, Anne Kristine, Lähteenmäki, Päivi M, Lepik, Kristi, El Hariry, Iman, Schmiegelow, Kjeld, and Albertsen, Birgitte Klug

Abstract

Asparaginase is essential in treating acute lymphoblastic leukaemia (ALL). Asparaginase-related hypersensitivity causes treatment discontinuation, which is associated with decreased event-free survival. To continue asparaginase treatment after hypersensitivity, a formulation of asparaginase encapsulated in erythrocytes (eryaspase) was developed. In NOR-GRASPALL 2016 (NCT03267030) the safety and efficacy of eryaspase was evaluated in 55 patients (aged 1–45 years; median: 6.1 years) with non-high-risk ALL and hypersensitivity to asparaginase conjugated with polyethylene glycol (PEG-asparaginase). Eryaspase (150 u/kg) was scheduled to complete the intended course of asparaginase (1–7 doses) in two Nordic/Baltic treatment protocols. Forty-nine (96.1%) patients had asparaginase enzyme activity (AEA) ≥100 iu/l 14 ± 2 days after the first eryaspase infusion [median AEA 511 iu/l; interquartile range (IQR), 291–780], whereas six of nine (66.7%) patients had AEA ≥100 iu/l 14 ± 2 days after the fourth infusion (median AEA 932 iu/l; IQR, 496–163). The mean terminal half-life of eryaspase following the first infusion was 15.3 ± 15.5 days. Few asparaginase-related adverse events were reported; five patients (9.1%) developed clinical allergy associated with enzyme inactivation. Replacement therapy was successfully completed in 50 patients (90.9%). Eryaspase was well tolerated, and most patients had AEA levels above the therapeutic target after the first infusion. The half-life of eryaspase confirmed that a 2-week schedule is appropriate.

Published
2022

23. Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

Author

Hammel, Pascal, primary, El-Hariry, Iman, additional, Macarulla, Teresa, additional, Garcia-Carbonero, Rocio, additional, Metges, Jean-Philippe, additional, Bouché, Olivier, additional, Portales, Fabienne, additional, Pazo Cid, Roberto A., additional, Mineur, Laurent, additional, Cubillo Gracian, Antonio Manuel, additional, Trouilloud, Isabelle, additional, Guimbaud, Rosine, additional, Tougeron, David, additional, Reina Zoilo, Juan Jose, additional, Feliu, Jaime, additional, Sauri, Tamara, additional, Fountzilas, Christos, additional, Kay, Richard, additional, Youssoufian, Hagop, additional, and Hidalgo, Manuel, additional

Published
2022
Full Text
View/download PDF

24. A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.

Author

Yin, Chao, primary, Marshall, John, additional, Macke, Laura, additional, Bouker, Kerrie, additional, He, Aiwu Ruth, additional, Weinberg, Benjamin Adam, additional, Weiner, Louis M., additional, Wang, Hongkun, additional, Badri, Nabeel, additional, Biswas-Baldwin, Nigel, additional, Hoke, Frank, additional, Youssoufian, Hagop, additional, El-Hariry, Iman, additional, and Noel, Marcus Smith, additional

Published
2022
Full Text
View/download PDF

26. Expanded Access Program: Evaluating Safety of Erythrocytes Encapsulating L-Asparaginase in Combination with Polychemotherapy in Patients Under 55 Years Old with Acute Lymphoblastic Leukaemia (ALL) at Risk to Receive Other Formulations of Asparaginase

Author

Bertrand, Yves, primary, Boissel, Nicolas, additional, Schmitt, Claudine, additional, Villate, Alban, additional, Gyan, Emmanuel, additional, Quesnel, Bruno, additional, Recher, Christian, additional, Simon, Pauline, additional, Cheikh, Nathalie, additional, Poirée, Marilyne, additional, Stephan, Jean, additional, Dumesnil, Cecile, additional, and El-Hariry, Iman, additional

Published
2021
Full Text
View/download PDF

33. A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.

Author

Noel, Marcus Smith, primary, Philip, Philip Agop, additional, Tejani, Mohamedtaki Abdulaziz, additional, Marshall, John, additional, He, Aiwu Ruth, additional, Weinberg, Benjamin Adam, additional, Weiner, Louis M., additional, Biswas-Baldwin, Nigel, additional, Hoke, Frank, additional, Youssoufian, Hagop, additional, and El-Hariry, Iman, additional

Published
2021
Full Text
View/download PDF

35. TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).

Author

Hammel, Pascal, primary, Berardi, Rossana, additional, Creemers, Geert-Yan, additional, Cubillo, Antonio, additional, Van Cutsem, Eric, additional, Greil, Richard, additional, Macarulla, Teresa, additional, Metges, Jean-Philippe, additional, Noel, Marcus Smith, additional, Nygren, Peter, additional, Osterlund, Pia J., additional, Seufferlein, Thomas, additional, Wasan, Harpreet Singh, additional, Gupta, Anu, additional, Grummer, Linda Marie, additional, Biswas-Baldwin, Nigel, additional, Kay, Richard, additional, Youssoufian, Hagop, additional, El-Hariry, Iman, additional, and Hidalgo, Manuel, additional

Published
2020
Full Text
View/download PDF

36. Circulating tumor DNA is prognostic and potentially predictive of eryaspase efficacy in patients with advanced pancreatic adenocarcinoma.

Author

Bachet, Jean-Baptiste, primary, Blons, Helene, additional, Hammel, Pascal, additional, El Hariry, Iman, additional, Portales, Fabienne, additional, Mineur, Laurent, additional, Metges, Jean-Philippe, additional, Mulot, Claire, additional, Bourreau, Camille, additional, Cain, Jason, additional, Cros, Jerome, additional, and Laurent-Puig, Pierre, additional

Published
2020
Full Text
View/download PDF

37. Erratum to ‘Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial’ [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]

Author

Hammel, Pascal, primary, Portales, Fabienne, additional, Mineur, Laurent, additional, Metges, Jean-Philippe, additional, Andre, Thierry, additional, De La Fouchardiere, Christelle, additional, Louvet, Christophe, additional, El Hajbi, Farid, additional, Faroux, Roger, additional, Guimbaud, Rosine, additional, Tougeron, David, additional, Bouche, Olivier, additional, Lecomte, Thierry, additional, Rebischung, Christine, additional, Tournigand, Christophe, additional, Cros, Jerome, additional, Kay, Richard, additional, Hamm, Adam, additional, Gupta, Anu, additional, Bachet, Jean-Baptiste, additional, and El Hariry, Iman, additional

Published
2020
Full Text
View/download PDF

38. Abstract OT1-08-02: TRYbeCA-2: A randomized phase 2/3 study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer (NCT03674242)

Author

Awada, Ahmad, primary, Cortes, Javier, additional, Slater, Sarah, additional, MacPherson, Iain, additional, Csoszi, Tibor, additional, Bertrand, Jean-Baptiste, additional, Clermont, Anne-Sophie, additional, Pollard, Rachel, additional, Chrestia-Blanchine, Romain, additional, Biswas-Baldwin, Nigel, additional, Youssoufian, Hagop, additional, and El-Hariry, Iman, additional

Published
2020
Full Text
View/download PDF

40. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

Author

Wulfing, Christian, Machiels, Jean-Pascal H., Richel, Dirk J., Grimm, Marc-Oliver, Treiber, Uwe, De Groot, Marco R., Beuzeboc, Philippe, Parikh, Roma, Petavy, Frank, and El-Hariry, Iman A.

Subjects
Adenocarcinoma -- Care and treatment, Adenocarcinoma -- Patient outcomes, Adenocarcinoma -- Research, Bladder cancer -- Care and treatment, Bladder cancer -- Patient outcomes, Bladder cancer -- Research, Health
Published
2009

41. Abstract B22: Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Author

Hammel, Pascal, primary, Berardi, Rosanna, additional, Cutsem, Eric Van, additional, Feliu, Jaime, additional, Greil, Richard, additional, Wasan, Harpreet, additional, Metges, Jean-Philippe, additional, Nygren, Peter, additional, Österlund, Pia, additional, Noel, Marcus, additional, Seufferlein, Thomas, additional, Creemers, Geert-Jan, additional, Gupta, Anu, additional, Salesse, Sophie, additional, Biswas-Baldwin, Nigel, additional, Dion, Hedy, additional, Youssoufian, Hagop, additional, El-Hariry, Iman, additional, and Hidalgo, Manuel, additional

Published
2019
Full Text
View/download PDF

42. Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).

Author

Hammel, Pascal, primary, Berardi, Rossana, additional, Van Cutsem, Eric, additional, Feliu, Jaime, additional, Greil, Richard, additional, Wasan, Harpreet Singh, additional, Metges, Jean-Philippe, additional, Nygren, Peter, additional, Osterlund, Pia J., additional, Parner, Vibeke, additional, Seufferlein, Thomas, additional, Gupta, Anu, additional, Salesse, Sophie, additional, Biswasbaldwin, Nigel, additional, Ibrahim, Ayman, additional, Youssoufian, Hagop, additional, El-Hariry, Iman, additional, and Hidalgo, Manuel, additional

Published
2019
Full Text
View/download PDF

45. A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).

Author

Hammel, Pascal, primary, Bachet, Jean-Baptiste, additional, El-Hariry, Iman, additional, Portales, Fabienne, additional, Mineur, Laurent, additional, Metges, Jean-Philippe, additional, De La Fouchardiere, Christelle, additional, Louvet, Christophe, additional, El Hajbi, Farid, additional, Faroux, Roger, additional, Guimbaud, Rosine, additional, Tougeron, David, additional, Volet, Julien, additional, Lecomte, Thierry, additional, Tournigand, Christophe, additional, Rebischung, Christine, additional, Berlier, Willy, additional, Gupta, Anu, additional, Cros, Jerome, additional, and Andre, Thierry, additional

Published
2017
Full Text
View/download PDF

46. Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01 51851 7)

Author

Thomas, Xavier, Bertrand, Yves, Baruchel, Andre, Blin, Nicolas, Tavernier, Emmanuelle, Ducassou, Stephane, Norbert Vey, Gandemer, Virginie, Cacheux, Victoria, Mazingue, Francoise, Raffoux, Emmanuel, Plat, Genevieve, Fernandes, Jose, Poiree, Maryline, Fornecker, Luc, Stephan, Jean-Louis, Hunault, Mathilde, Auvrignon, Anne, Leguay, Thibault, Lepretre, Stephane, Ferster, Alina, Pellier, Isabelle, Plouvier, Emmanuel, Schmitt, Claudine, Bonin, Cecile, Godfrin, Yann, El Hariry, Iman, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Hématologie et immunologie pédiatrique, Hospices Civils de Lyon (HCL)-CHU Lyon-Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL)-Hôpital Femme-Mère-Enfant (HFME), Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Hôpital Pellegrin Tripode, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Pediatric Onco-Hematology Unit, CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), CHU Clermont-Ferrand, Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pédiatrie, Unité d'Oncologie et Hématologie Pédiatrique, Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hématologie pédiatrique, CHU Saint-Etienne, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pédiatrie, CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'Hématologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV]Life Sciences [q-bio]
Abstract

WOS:000368020102004; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015

Published
2015

49. Expanded Access Program of GRASPA for treatment of patients with acute lymphoblastic leukemia unable to receive other form of L-Asparaginase: A status update (NCT02197650).

Author

Bertrand, Yves, primary, Dombret, Herve, additional, Quesnel, Bruno, additional, Lissandre, Severine, additional, Schmitt, Claudine, additional, Plouvier, Emmanuel, additional, Recher, Christian, additional, Poiree, Maryline, additional, DUMESNIL de MARICOURT, Cecile, additional, and El-Hariry, Iman, additional

Published
2016
Full Text
View/download PDF

50. EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma

Author

Lalami, Yassine, Specenier, Pol M., Awada, Ahmad, Lacombe, Denis, Liberatoscioli, Cecilia, Fortpied, Catherine, El-Hariry, Iman, Bogaerts, Jan, Andry, Guy, Langendijk, J.A., and Vermorken, Jan B.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results